Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cellular therapy for haematological malignancies.

P H Roddie1, M L Turner

  • 1SNBTS Cell Therapeutics Group, University of Edinburgh-Leukaemia Research Fund, John Hughes Bennett Laboratory, Edinburgh, UK. huw.roddie@luht.scot.nhs.uk

Vox Sanguinis
|November 20, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Enhancing electron affinity and tuning band gap in donor-acceptor organic semiconductors by benzothiadiazole directed C-H borylation.

Chemical science·2017
Same author

Identifying viable regulatory and innovation pathways for regenerative medicine: a case study of cultured red blood cells.

New biotechnology·2014
Same author

Use of IL3 and chromatin-modifying reagents valproic acid and 5-aza-2'-deoxycytidine to affect mobilized peripheral blood CD34+ cell fate decisions.

Vox sanguinis·2014
Same author

Quantal and graded stimulation of B lymphocytes as alternative strategies for regulating adaptive immune responses.

Nature communications·2013
Same author

UK approach to assessing assays and filters designed to reduce the risk of transfusion-transmitted vCJD.

Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine·2013
Same author

Drug modification of LPS-stimulated human monocyte-derived dendritic cells.

British journal of biomedical science·2012
Same journal

Red cell alloantibodies in 71,525 Malaysian blood donations: Predominance of anti-Mia reflects GP.Mur-associated antigenic diversity.

Vox sanguinis·2026
Same journal

Barriers and enablers to non-remunerated plasma donation: A meta-synthesis of the qualitative literature using the theoretical domains framework.

Vox sanguinis·2026
Same journal

Haemolytic disease of the foetus and newborn due to anti-M: A systematic review.

Vox sanguinis·2026
Same journal

In vitro evaluation of apheresis platelet and plasma products collected and stored in non-DEHP disposable sets.

Vox sanguinis·2026
Same journal

Survey of national and regional rare donor programmes regarding Immunoglobulin A deficiency.

Vox sanguinis·2026
Same journal

Fibrinogen recovery in cryoprecipitate prepared from thawed plasma stored for 5 days post-thaw.

Vox sanguinis·2026
See all related articles

This review highlights advancements in cellular therapeutics for blood cancers. It explores how National Transfusion Services can aid in manufacturing these novel agents, ensuring regulatory compliance.

Area of Science:

  • Hematology
  • Cellular Therapeutics
  • Immunotherapy

Background:

  • Cellular therapy is rapidly advancing for hematological malignancies.
  • Novel cellular products are increasingly used in clinical settings.
  • Hematopoietic stem cell transplantation and immunotherapy are key areas of application.

Purpose of the Study:

  • To review recent progress in cellular therapeutics for blood cancers.
  • To examine the potential role of National Transfusion Services in manufacturing these agents.
  • To assess the benefits of collaboration for meeting regulatory standards.

Main Methods:

  • Literature review of recent advancements in cellular therapy.
  • Analysis of the capabilities of National Transfusion Services.

Related Experiment Videos

  • Examination of regulatory requirements for cell-based therapies.

    • Main Results:

    • Significant progress has been made in cellular therapeutics for hematological malignancies.
    • National Transfusion Services possess expertise and facilities suitable for manufacturing cellular agents.
    • Collaboration can help meet stringent regulatory demands.

    Conclusions:

    • Cellular therapy is a growing field with increasing clinical applications.
    • National Transfusion Services are well-positioned to support the production of novel cellular therapies.
    • Partnerships are crucial for fulfilling regulatory standards in cellular product manufacturing.